Nuvaira
Nuvaira is a clinical-stage medical device company developing the dNerva Lung Denervation System, a catheter-based radiofrequency platform that performs one-time outpatient bronchoscopic procedures to disrupt pulmonary nerves and treat moderate-to-severe COPD patients who remain symptomatic on inhaled therapy.
- Company typePrivate
- Founded2008
- HeadquartersMinneapolis, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nuvaira does
Nuvaira is a clinical-stage medical device company headquartered in Minneapolis, Minnesota, founded in 2008 to develop catheter-based therapies for overactive airway nerves in chronic obstructive pulmonary disease (COPD). Its core product, the dNerva Lung Denervation System, performs Targeted Lung Denervation (TLD) — a one-time, 60–90 minute outpatient bronchoscopic procedure under general anesthesia in which a balloon-mounted radiofrequency catheter delivers circumferential ablation to pulmonary nerve branches in the main bronchi, permanently disrupting parasympathetic acetylcholine release to produce a durable "always on" bronchodilator effect. The system comprises the disposable dNerva RF catheter (available in three sizes for 9–16.5 mm bronchi), the Nuvaira Console (RF generator with thermoelectric cooling and graphical interface), and the optional EsoCool esophageal cooling catheter; its DualCool technology simultaneously cools the airway wall and esophagus during RF delivery to protect surrounding tissue. The company serves pulmonologists, interventional bronchoscopists, and moderate-to-severe COPD patients who remain symptomatic on dual or triple inhaled therapy, with clinical development conducted across 40 sites in the US (25) and Europe (15) under the AIRFLOW-3 pivotal trial (N=464).
Nuvaira holds FDA Breakthrough Device Designation (2020-2021) and CE Mark approval for EU commercialization, with more than 70 patents issued and pending worldwide and 18 peer-reviewed publications supporting safety and a 62% reduction in severe exacerbation risk at two years. The company is pre-revenue in the US (device under IDE investigation, not commercially available), with planned commercialization through direct hospital sales of capital equipment consoles plus recurring disposable catheter revenue. The business has been funded through venture capital rounds totaling approximately $178 million in disclosed financing ($49M in 2014-2015, $79M in 2019, $50M in 2022) plus active exempt securities offerings through 2026, with no commercial product revenue disclosed.
Nuvaira firmographics
Firmographics- Name
- Nuvaira
- Legal name
- Nuvaira, Inc.
- Website
- https://nuvaira.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Nuvaira is a clinical-stage medical device company developing the dNerva Lung Denervation System, a catheter-based radiofrequency platform that performs one-time outpatient bronchoscopic procedures to disrupt pulmonary nerves and treat moderate-to-severe COPD patients who remain symptomatic on inhaled therapy.
- Ownership category
- akta.pro rank
Nuvaira industry classification
Industry- Product category
- Interventional Pulmonology Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- COPD & Chronic Bronchitis Management (HLAKANAE)
- akta.pro secondary industry
- Bronchoscopy & Interventional Pulmonology (HLAKANAJ)
Keywords
Where Nuvaira is headquartered
LocationHeadquarters
- HQ city
- Minneapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nuvaira business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales (Post-Regulatory Approval): Nuvaira is a clinical-stage medical device company. The dNerva Lung Denervation System has CE Mark regulatory approval (EU) and is under FDA pivotal investigation in the US. Revenue will be generated from direct hospital sales of the dNerva system (catheters, console) upon regulatory approvals. The system includes a console (capital equipment) and disposable catheters, creating a recurring revenue opportunity through procedural consumables.
- Financing/Exempt Securities Offerings: Nuvaira has raised capital through multiple exempt securities offerings under SEC Rule 506(b). The company has sold approximately $35.76 million of a $63.58 million offering as of February 2026, with prior offerings of $17.25 million (2023) and $68.23 million (2022). These are not revenue from operations but capital raises to fund R&D and clinical trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | dNerva Lung Denervation System - Not commercially available in USA |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Nuvaira product offering
Product offeringCore offering
Nuvaira develops and commercializes the dNerva Lung Denervation System, a catheter-based medical device platform that performs Targeted Lung Denervation (TLD) for the treatment of moderate-to-severe COPD. The system consists of a disposable dNerva RF ablation catheter, the Nuvaira Console (capital equipment), and the EsoCool esophageal cooling catheter, which together deliver a one-time 60-90 minute outpatient bronchoscopic procedure that permanently disrupts pulmonary nerve input to create a durable bronchodilator effect.
Product overview
Nuvaira offers the dNerva Lung Denervation System, a novel catheter-based medical device platform for treating COPD through Targeted Lung Denervation (TLD). The system consists of the dNerva RF ablation catheter (disposable, available in multiple sizes for different bronchi diameters), the Nuvaira Console (which houses the RF generator, thermoelectric cooling plate, and pump), and the EsoCool esophageal cooling catheter for tissue protection. The DualCool technology feature enables simultaneous RF energy delivery and cooling. This is a single primary product with multiple component and feature variations—a complete therapeutic system for a one-time outpatient bronchoscopic procedure.
Differentiator
Problem solved
Functional benefit
Brands
- dNerva Lung Denervation System: A catheter-based system used to complete a one-time, out-patient, bronchoscopic procedure to disrupt nerve input to and from the lungs to reduce the clinical consequences of neural hyperactivity.
- DualCool
- EsoCool
Products and services
- dNerva Lung Denervation System Catheter-based medical device system that performs Targeted Lung Denervation (TLD), a one-time 60-90 minute outpatient bronchoscopic procedure under general anesthesia that permanently disrupts pulmonary nerve input to the lungs to reduce the clinical consequences of neural hyperactivity in moderate-to-severe COPD patients. The system comprises the dNerva RF catheter, the Nuvaira Console, and the optional EsoCool esophageal cooling catheter.
- Nuvaira Console Capital equipment console including a thermoelectric plate and pump that cools fluid circulating through the dNerva catheter to protect the airway wall during RF energy delivery. Features a graphical user interface with a prompt screen to control the console and guide the user through the Targeted Lung Denervation procedure.
- EsoCool Esophageal Cooling Catheter Esophageal cooling catheter designed for protection during lung denervation that actively cools the esophagus throughout RF ablation, providing additional tissue protection during the Targeted Lung Denervation procedure.
Quantifiable outcome
- 62% reduction in risk of severe COPD exacerbations at 2 years (AIRFLOW-2 trial)
- +5 more outcomes
Companies that use Nuvaira
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Nuvaira technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nuvaira partnerships and signals
Strategic signalScale indicators10 records
Recent moves6 records
Expansion highlights5 records
Nuvaira competitors and assessment
Company assessmentDirect peers
- Pulmonx: Pulmonx markets the Zephyr Endobronchial Valve, a bronchoscopic device for lung volume reduction in emphysema/COPD patients. It is the closest direct procedural peer to Nuvaira in interventional pulmonology targeting severe COPD, sharing the same specialist customer base, bronchoscopic delivery model, and need for specialty reimbursement.
- Spiration (Olympus): Spiration, a subsidiary of Olympus, produces the Spiration Valve System for bronchoscopic lung volume reduction in emphysema patients. It competes directly in the interventional COPD procedural space with Nuvaira's dNerva, sharing the bronchoscopic, specialist-delivered model and severe-COPD patient population.
- PneumRx (Boston Scientific): PneumRx, acquired by BTG (now Boston Scientific), developed the RePneu Coil for bronchoscopic lung volume reduction in emphysema. It is a direct procedural peer to Nuvaira in interventional COPD therapy and shares the bronchoscopic, hospital-based, specialist-physician delivery model.
Broad incumbents
- Olympus: Olympus is the dominant manufacturer of flexible bronchoscopes and a broad portfolio of interventional pulmonology devices. As the platform on which Nuvaira's dNerva catheter is delivered, Olympus is both a critical enabling partner and a broad incumbent whose portfolio could expand to compete with or absorb TLD-like technologies.
- Boston Scientific: Boston Scientific owns PneumRx and operates a large interventional pulmonology and chronic respiratory device portfolio. It is a broad incumbent that competes in procedural COPD therapy and is a likely strategic acquirer of Nuvaira if TLD reaches commercial approval.
- Medtronic: Medtronic offers bronchoscopy-enabled diagnostics and therapies (including acquired superDimension navigation) and competes in interventional pulmonology broadly. It is a broad incumbent whose portfolio overlaps with the procedural COPD space and could view Nuvaira as complementary.
Emerging players
- Body Vision Medical: Body Vision Medical develops AI-driven bronchoscopic lung navigation and biopsy tools for pulmonary nodules. While focused on diagnostics rather than COPD treatment, it is an emerging player sharing the bronchoscopic, pulmonologist-targeted commercial channel that Nuvaira depends on.
- Broncus Medical: Broncus Medical develops interventional pulmonology tools including lung navigation and biopsy systems for COPD and lung cancer. It is an emerging player operating in the same bronchoscopic, pulmonologist channel and addressing overlapping patient populations.
- Inspire Medical Systems: Inspire Medical Systems developed an implanted neurostimulation device for obstructive sleep apnea, sharing with Nuvaira a procedural, neuromodulation-based approach to airway disease. Inspire's CEO also chairs Nuvaira's board, signaling strategic and operational adjacency between the two device platforms.
Others
- AstraZeneca: AstraZeneca is a leading COPD pharmaceutical manufacturer (Symbicort, Breztri, Fasenra) whose triple-therapy and biologic inhaler portfolios compete for the same moderate-to-severe COPD patient population. It is thematically adjacent as the dominant incumbent pharmacotherapy whose continued innovation could narrow TLD's addressable pool.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Nuvaira social profiles
Digital presenceNuvaira compliance and trust
Trust signalCompliance2 records
Nuvaira financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nuvaira leadership team
Management profileNumber of profiles
Profiles11 records
Nuvaira funding detail
Funding detailFunding overview
Funding rounds13 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nuvaira M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nuvaira
What does Nuvaira do?
Nuvaira develops and commercializes the dNerva Lung Denervation System, a catheter-based medical device platform that performs Targeted Lung Denervation (TLD) for the treatment of moderate-to-severe COPD. The system consists of a disposable dNerva RF ablation catheter, the Nuvaira Console (capital equipment), and the EsoCool esophageal cooling catheter, which together deliver a one-time 60-90 minute outpatient bronchoscopic procedure that permanently disrupts pulmonary nerve input to create a durable bronchodilator effect.
Is Nuvaira a public or private company?
Nuvaira is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nuvaira founded?
Nuvaira was founded in 2008. It employs 51 to 100 people.
Where is Nuvaira based?
Nuvaira is headquartered in Minneapolis, United States, in the North America region.
How does Nuvaira make money?
Two revenue lines are on record. Medical Device Sales (Post-Regulatory Approval) is the primary driver. The others are financing/Exempt Securities Offerings.
Who are Nuvaira's main competitors?
Direct peers on record are Pulmonx, Spiration (Olympus) and PneumRx (Boston Scientific). Broad incumbents are Olympus, Boston Scientific and Medtronic. Emerging players are Body Vision Medical, Broncus Medical and Inspire Medical Systems. AstraZeneca is listed as an others.
Does Nuvaira have an API?
No public API is recorded for Nuvaira.
What industry is Nuvaira in?
Nuvaira's product category is Interventional Pulmonology Medical Devices. Its primary akta.pro industry code is HLAKANAE, COPD & Chronic Bronchitis Management, with a secondary code of HLAKANAJ, Bronchoscopy & Interventional Pulmonology. Its NAICS code is 339113 and its SIC code is 3841.